- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights
Nightstar Therapeutics (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today reported financial results for the year ended December 31, 2017 and provided an update on recent corporate and clinical highlights. As quoted in the press release: “2017 was an exceptional year for the company,” said Dave Fellows, Chief Executive …
Nightstar Therapeutics (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today reported financial results for the year ended December 31, 2017 and provided an update on recent corporate and clinical highlights.
As quoted in the press release:
“2017 was an exceptional year for the company,” said Dave Fellows, Chief Executive Officer. “We set the stage for the recent initiation of the first-ever Phase 3 trial in choroideremia and today announced further data supporting the durability of the treatment effect for NSR-REP1 in choroideremia. Elsewhere in our pipeline, we initiated our Phase 1/2 gene therapy trial for X-linked retinitis pigmentosa and in-licensed our program for Stargardt disease. We also raised more than $130 million of gross proceeds from our successful Series C financing and IPO to continue our pioneering research and development activities.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.